All News

Found 562 articles

• Regeneron Reports First Quarter 2017 Financial And Operating Results

  5/4/2017

• Sanofi Delivers Robust Q1 2017 Financial Results

  4/28/2017

• These 3 Big Biotechs Could Have New Blockbuster Drugs Very Soon

  4/10/2017

• Massive $1.2 Billion Biotech Center in New York Will Create Thousands of New Jobs

  4/7/2017

• Sanofi Genzyme Head to Leave After 23 Years on the Job, Replacement Named

  4/6/2017

• This Game-Changing Drug Could Be Regeneron's Next Blockbuster

  3/30/2017

• Sanofi And Regeneron Announce FDA Approval Of Dupixent (Dupilumab), The First Targeted Biologic Therapy For Adults With Moderate-To-Severe Atopic Dermatitis

  3/28/2017

• Regeneron And Sanofi Announce Presentation Of Positive Data From Long-Term Pivotal Phase III CHRONOS Study Of DUPIXENT (Dupilumab) In Moderate-To-Severe Atopic Dermatitis

  3/6/2017

• 6 Biotechs Facing Key FDA Decisions in March

  3/2/2017

• Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results

  2/9/2017

• Sanofi Delivers 2016 Sales And Business EPS Growth At CER

  2/8/2017

• 5 Highest Paid Biopharma CEOs of 2016

  2/7/2017

• 7 Biotech Stocks to Watch in 2017

  1/3/2017

• A Turnaround: Regeneron Eyes a Comeback in 2017

  12/28/2016

• Booming Regeneron Buys Another Building in New York

  12/16/2016

• Sanofi to Cut 20 Percent of its U.S. Diabetes Workforce

  12/12/2016

• Regeneron And Sanofii Announce Marketing Authorization Application For Dupixent (Dupilumab) Accepted For Review By The EMA

  12/8/2016

• Regeneron Reports Third Quarter 2016 Financial And Operating Results

  11/4/2016

• Deficiencies Found at Manufacturing Site Could Delay Approval of Sanofi Genzyme's Next Blockbuster

  10/31/2016

• Sanofi Announces Strong Q3 2016 Results

  10/28/2016